FytonBio is a privately held, preclinical-stage biopharmaceutical company specializing in biotechnology research. Their core mission is to achieve functional cures for autoimmune and inflammatory diseases by deleting pathogenic immune cells. The company focuses on developing monoclonal antibodies capable of highly specific depletion of such cells